Introduction
============

Based on the results of the first European point prevalence survey (PPS) in 2011--12 an estimated 3.2 million patients acquire a healthcare-associated infection (HCAI) in acute care hospitals in Europe every year \[[@r1]\]. The most common types of HCAI are surgical site infections (SSI), urinary tract infections (UTI), pneumonia (PN), bloodstream infections (BSI), and gastrointestinal infections, with *Clostridium difficile* infection (CDI) accounting for a high proportion in the latter. HCAIs result in increased morbidity and mortality, and emerging [antibiotic resistance](https://en.wikipedia.org/wiki/Antibiotic_resistance) complicates their [treatment](https://en.wikipedia.org/wiki/Medical_case_management). The cumulative burden of HCAIs is higher than the total burden of other communicable diseases in Europe \[[@r2]\].

Surveillance as the 'ongoing systematic collection and analysis of health data for the planning, implementation, and evaluation, of public health practice' \[[@r3]\] is a key measure in HCAI prevention and control. Even in the absence of specific prevention actions, surveillance and feedback of outcome indicators decrease HCAI by raising awareness for the issue among healthcare professionals \[[@r4]-[@r7]\]. Surveillance, preferably as part of a network, was identified as one of the key components in effective HCAI prevention and an important tool for monitoring the effectiveness of prevention and control measures by the 'Systematic Review and Evidence-based Guidance on Organization of Hospital Infection Control Programmes' (SIGHT) project \[[@r8]\].

Since the 1990s, many European countries have been developing national surveillance networks, either by applying the United States' (US) Centers for Disease Control and Prevention (CDC) National Nosocomial Infection Surveillance/National Healthcare Safety Network (NNIS/NHSN) protocol, or by using adapted methods to better take into account local diagnostic practices \[[@r9]\]. In 2010, the European Centre for Disease Prevention and Control (ECDC) established the Healthcare-Associated Infections surveillance Network (HAI-Net), integrating the Hospitals in Europe Link for Infection Control through Surveillance (HELICS) project (2000--4) and the Improving Patient Safety in Europe (IPSE) network (2005--8) \[[@r10]\].

Surveillance of alcohol-based hand rub (ABHR) consumption has become a mandatory quality indicator with public reporting in France since 2006 \[[@r11]\], and was integrated into the national Krankenhaus-Infektions-Surveillance-System (KISS) in 2008 in Germany \[[@r12]\]. Furthermore, national strategies on measuring hand hygiene compliance by direct observation have been organised in a number of European countries \[[@r13]\].

Aspects of specific surveillance activities in European hospitals were obtained as part of the Prevention of Hospital Infections by Intervention and Training (PROHIBIT) project. The PROHIBIT survey was conducted as the first pan-European survey on infection prevention and control (IPC) in order to describe which IPC recommendations are actually being used across Europe and to provide information on gaps in hospitals' IPC policies and practices for policymakers, hospital managers and healthcare workers for further improvement of HCAI prevention. This article summarises data on findings from 24 European countries.

Methods
=======

Participating countries and hospitals
-------------------------------------

ECDC national contact points (NCPs) and IPC experts of European countries outside of the European Union (EU) were invited to organise national polls. The NCPs invited national hospitals for participation between September 2011 and March 2012. Participation in the PROHIBIT survey was based mainly on hospital interest rather than on a systematic sampling process.

Survey description
------------------

The survey was developed by an interdisciplinary group and discussed with the HAI-Net representatives. It included four questionnaires in order to assess IPC structure and process indicators (i) at the hospital level, (ii) in intensive care units (ICU), (iii) in non-ICU medical wards and (iv) in non-ICU surgical wards. Questionnaires addressed organisation and activities of IPC at those various levels.

The complete method of the survey and the characteristics of the participating hospitals are described in more detail elsewhere \[[@r14]\].

For the present analysis, data on HCAI surveillance, process and outcome indicators (e.g. ABHR consumption, HCAI), direct hand hygiene observations, feedback practices, and persons performing surveillance are described at hospital level. Hospitals were asked whether the following multidrug-resistant organisms (MDRO) were monitored among HCAI: meticillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant Enterococci (VRE), extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, carbapenem nonsusceptible or carbapenemase-producing Enterobacteriaceae, carbapenem-resistant *Pseudomonas aeruginosa* and multiresistant *Acinetobacter baumannii.*

Local IPC professionals were also asked to provide data on hospital characteristics such as status (public/private) and size of the hospital (number of beds), and the full time equivalent (FTE) of infection control personnel.

Furthermore, country characteristics such as the United Nations (UN) European geographical region, and healthcare expenditure (HCE) as share on the national gross domestic product (GDP) were collected \[[@r15],[@r16]\].

Data analysis
-------------

Descriptive data analysis was performed and results summarised as totals and strata of the following four parameters: hospital size (small: ≤ 300 beds; medium: 301--600 beds; large: \> 600 beds), UN European geographical regions, full-time-equivalent (FTE) infection control nurses (ICN) (internal staff and external staff) per 1,000 acute care hospital beds ≤ / \> the median of all participating hospitals (3.72 FTE ICN/1,000 beds) and HCE as share on GDP \[[@r15],[@r16]\]. HCE was modelled as a dichotomous variable and considered low or high if below or above the European mean HCE of 9%. Differences in the process and outcome indicators between the strata of the four parameters described above were tested by logistic regressions models. In the regression analysis with indicator parameters as outcome, only the independent variables were included in the generalised estimating equation (GEE) models, adjusting for cluster effects by country. A two-sided p value \< 0.05 in the type III test was considered significant. All analyses were performed with SPSS (IBM SPSS statistics, Somer, NY, US) and SAS (SAS Institute, Cary, NC, US).

Results
=======

Participating countries and hospitals
-------------------------------------

Of 32 invited countries, 24 participated ([Table 1](#t1){ref-type="table"}) with 309 acute care hospitals. From all 309 acute care hospitals participating in the PROHIBIT survey, 297 hospitals (96%) had some method of HCAI surveillance in place. Hospitals with HCAI surveillance had a median of 426 beds (interquartile range (IQR): 260--277), and were most often public hospitals (253 hospitals, 85%).

###### Distribution of hospitals providing data on healthcare-associated infection surveillance and national healthcare expenditure as part of the gross domestic product by country -- the Prevention of Hospital Infection by Intervention and Training (PROHIBIT) survey, Europe, 2011--2012 (n = 297 hospitals)

  United Nations region^a^   Country    Total HCE as % of GDP^b^   Number of participating hospitals   
  -------------------------- ---------- -------------------------- ----------------------------------- -----
  Northern Europe, n = 70    Finland    8.9                        11                                  3.7
  Ireland                    9.2        12                         4                                   
  Latvia                     6.8        7                          2.4                                 
  Lithuania                  7          13                         4.4                                 
  Sweden                     9.6        6                          2                                   
  United Kingdom, England    9.6        5                          1.7                                 
  United Kingdom, Scotland   3          1                                                              
  United Kingdom, Wales      13         4.3                                                            
  Eastern Europe, n = 82     Bulgaria   7.2                        19                                  6.4
  Hungary                    7.8        30                         10.1                                
  Poland                     7          9                          3                                   
  Slovakia                   9          24                         8.1                                 
  Southern Europe, n = 81    Croatia    7.8                        5                                   1.7
  Italy                      9.3        18                         6.1                                 
  Malta                      8.6        1                          0.3                                 
  Portugal                   10.7       26                         8.8                                 
  Slovenia                   9          8                          2.7                                 
  Spain                      9.6        23                         7.7                                 
  Western Europe, n = 64     Austria    11                         8                                   2.7
  Belgium                    10.5       5                          1.7                                 
  France                     11.6       8                          2.7                                 
  Germany                    11.6       29                         9.8                                 
  Switzerland                11.4       6                          2                                   
  The Netherlands            12         8                          2.7                                 
  All                        NA         NA                         297                                 100

GDP: gross domestic product; HCE: healthcare expenditure; NA: not applicable.

**^a^**Geographical regions according to United Nations grouping \[[@r15]\].

**^b^**HCE as the share of the GDP \[[@r16]\].

Medical conditions/disease outcome where HCAI surveillance applies
------------------------------------------------------------------

Surveillance in the hospitals mainly focused on SSI and BSI, and less often on PN, CDI and UTI ([Table 2](#t2){ref-type="table"}). Surveillance of UTI depended on countries' HCE with significantly higher proportions in countries with low HCE. For PN, significant differences were observed in accordance to the hospital size, with more medium to large hospitals having PN surveillance in place compared to smaller hospitals. Significantly more hospitals from countries with low HCE performed hospital-wide surveillance of PN and UTI. Hospital-wide surveillance of BSI varied significantly with the UN regions.

###### Surveillance of process and outcome indicators in European acute care hospitals, stratified by healthcare expenditure, United Nation regions, hospital size, rate of infection control nurses -- the Prevention of Hospital Infection by Intervention and Training (PROHIBIT) survey, 2011--2012 (n = 297 hospitals)

  Healthcare-associated infections under surveillance with particular procedures surveilled   Total   HCE^a^   United Nations region^b^   Hospital size^c^   ICN/1,000 beds^d^                                                                                               
  ------------------------------------------------------------------------------------------- ------- -------- -------------------------- ------------------ ------------------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----- ---- ----- ----
  Healthcare-associated infections under surveillance                                                                                                                                                                                                                        
  Bloodstream infections                                                                      251     85       112                        88                 139                 82   79   96   58   83   65   80   49   77   67   77   96   88   85   87   127   85   124   84
  • Hospital-wide^e,f^                                                                        175     59       91                         72                 84                  49   68   83   49   70   42   52   16   25   50   57   72   66   51   52   79    53   96    65
  Pneumonia^g^                                                                                211     71       103                        81                 108                 64   74   90   39   56   56   69   42   66   49   56   84   77   76   78   113   75   98    67
  • Hospital-wide^e,h^                                                                        97      33       67                         53                 30                  18   49   60   20   29   22   27   6    9    26   30   42   39   29   30   48    32   49    33
  Urinary tract infections^h^                                                                 187     63       101                        80                 86                  51   74   90   28   40   49   60   36   56   49   56   69   63   68   69   103   69   84    57
  • Hospital-wide^e,h^                                                                        109     37       72                         57                 37                  22   54   66   22   31   27   33   6    9    31   36   47   43   31   32   52    35   57    39
  *Clostridium difficile*-associated infections                                               203     68       76                         60                 127                 75   50   61   54   77   55   68   44   69   51   59   73   67   76   78   91    61   112   76
  • Hospital-wide^e^                                                                          191     64       71                         56                 120                 71   45   55   54   77   51   63   41   64   46   53   69   63   73   74   86    57   105   71
  SSI                                                                                         254     86       112                        88                 142                 84   75   91   63   90   62   77   54   84   68   78   92   84   91   93   129   86   125   85
  Procedures                                                                                                                                                                                                                                                                 
  Cholecystectomy                                                                             130     44       71                         56                 59                  35   48   59   22   31   33   41   27   42   31   36   57   52   42   43   71    47   59    40
  Colon surgery                                                                               129     43       56                         44                 73                  43   39   48   19   27   43   53   28   44   30   34   54   50   44   45   64    43   65    44
  Caesarean section                                                                           126     42       63                         50                 63                  37   45   55   35   50   23   28   23   36   26   30   54   50   44   45   62    41   64    44
  Hip prosthesis implantation                                                                 164     55       57                         45                 107                 63   32   39   48   69   48   59   36   56   40   46   65   60   56   57   75    50   89    61
  Knee prosthesis implantation                                                                138     46       42                         33                 96                  55   24   29   41   59   43   53   30   47   33   38   57   52   45   46   57    38   81    55
  Post discharge surveillance of SSI                                                          148     50       54                         43                 94                  55   35   43   40   57   43   53   30   47   39   45   59   54   48   49   64    43   84    57
  Monitoring of alcohol-based handrub consumption                                             236     79       105                        83                 131                 77   65   79   47   67   71   88   53   83   68   78   82   75   85   87   124   83   112   76
  • Hospital-wide^e^                                                                          215     72       95                         75                 120                 71   57   70   46   66   65   80   47   73   59   68   80   73   75   77   114   76   101   69
  Monitoring of hand hygiene compliance^f^                                                    231     78       101                        80                 130                 76   62   76   67   96   66   81   36   56   72   83   81   74   75   77   109   73   122   83
  • Hospital-wide^e,c^                                                                        173     58       79                         62                 94                  55   48   59   62   89   38   47   25   39   59   68   64   59   49   50   79    53   94    64

FTE: full time equivalent; HCE: healthcare expenditure; ICN: infection control nurse; SSI: surgical site infection.

P values were calculated by logistic regression using generalised estimating equations, which account for cluster effects by country.

^a^Low/high HCE defined as the share of the gross domestic product ≤ / \> the European mean in 2010 (9%) \[[@r16]\].

^b^Geographical regions according to United Nations grouping \[[@r15]\]; Eastern Europe, Northern Europe, Southern Europe, Western Europe.

^c^Hospital size according to number of acute care beds; ≤ 300 beds, 301 -- 600 beds, \> 600 beds; information available for 294 hospitals.

^d^FTE ICN (internal staff and external staff) per 1,000 acute care hospital beds ≤ / \> the median of all participating hospitals (3.72 FTE ICN/1,000 beds).

^e^ Hospital-wide describes that the surveillance takes place in all units and wards of the hospital.

^f^Differences between United Nations regions p \< 0.05*.*

^g^Differences between ≤ 300 beds / 301 -- 600 beds / \> 600 beds; p \< 0.05*.*

^h^Differences between low/high HCE; p \< 0.05*.*

Surveillance of CDI was reported most often by hospitals in Northern Europe and more often by hospitals in countries with high HCE; but these differences were not statistically significant.

Hip prosthesis implantation (HPRO) was the most common indicator operation of SSI surveillance with higher percentages in countries with high HCE; but these differences were not statistically significant. In 148 of 254 hospitals with SSI surveillance (58%), post-discharge surveillance (PDS) was in place.

Multidrug-resistant organisms surveyed among HCAIs
--------------------------------------------------

MRSA was the most commonly observed MDRO among HCAI in almost all hospitals (n = 273), followed by ESBL-producing Enterobacteriaceae(n = 243) and VRE (n = 228). Multidrug-resistant *Acinetobacter baumannii* surveillance was reported by 204 hospitals, carbapenem nonsusceptible or carbapenemase-producing Enterobacteriaceae by 189 hospitals, and carbapenem-resistant *Pseudomonas aeruginosa* by 185 hospitals.

Monitoring hand hygiene compliance
----------------------------------

Consumption of ABHR and hand hygiene compliance was observed in 79% and 78% of the hospitals, respectively ([Table 2](#t2){ref-type="table"}). Hospitals in countries in Northern Europe preferred monitoring hand hygiene compliance to monitoring ABHR consumption, while hospitals in countries in Western Europe preferred monitoring ABHR consumption to monitoring hand hygiene compliance ([Table 2](#t2){ref-type="table"}).

Operators involved in HCAI surveillance
---------------------------------------

[Table 3](#t3){ref-type="table"} summarises the operators involved in HCAI surveillance. Most surveillance activities are performed by IPC personnel. Although the overall numbers are low, it appeared that hospitals in countries of Northern Europe had a higher percentage of specific staff dedicated to surveillance of HCAI compared to other regions. In almost half of the hospitals, data on HCAI were collected by IPC personnel, whereas surveillance exclusively performed by ward personnel was by reported by 9% of all hospitals, and 18% of hospitals in Eastern Europe.

###### Personnel involved in data collection for healthcare-associated infection (HCAI) surveillance in European acute care hospitals with HCAI surveillance, stratified by healthcare expenditure, United Nation regions, hospital size and infection control nurse rate -- the Prevention of Hospital Infection by Intervention and Training (PROHIBIT) survey, 2011--2012 (n = 297 hospitals)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Personnel involved in data collection for HCAI surveillance                        Total   HCE^a^   United Nation region^b^   Hospital size^c^\            ICN/1,000 beds^d^                                                                                              
                                                                                                                                in terms of number of beds                                                                                                                  
  ---------------------------------------------------------------------------------- ------- -------- ------------------------- ---------------------------- ------------------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----- ----
  ICN^e^                                                                             217     73       70                        55                           147                 86   45   55   50   71   65   80   57   89   62   71   79   72   73   74   99   66   118   80

  Infection control physician^f^                                                     146     49       54                        43                           92                  54   34   41   36   51   51   63   25   39   32   37   54   50   58   59   79   53   67    46

  Ward nurse                                                                         61      21       31                        24                           30                  18   21   26   22   31   13   16   5    8    19   22   28   26   13   13   28   19   33    22

  Ward physician                                                                     97      33       39                        31                           58                  34   26   32   29   41   25   31   17   27   31   36   39   36   26   27   44   29   53    36

  Specific surveillance staff e.g. nurse or administrator                            9       3        5                         4                            4                   2    5    6    2    3    2    2    0    0    1    1    4    4    3    3    6    4    3     2

  Audit nurse                                                                        46      15       22                        17                           24                  14   13   16   18   26   9    11   6    9    10   11   16   15   19   19   23   15   23    16

  Infection control personnel exclusively (ICN and/or infection control physician)   143     48       56                        44                           87                  51   36   44   24   34   43   53   40   63   39   45   49   45   53   54   76   51   67    46

  Ward personnel exclusively (ward nurse and/or ward physician)                      27      9        19                        15                           8                   5    15   18   7    10   4    5    1    2    13   15   12   11   2    2    14   9    13    9

  Infection control personnel and ward personnel                                     97      33       38                        30                           59                  35   24   29   29   41   27   33   17   27   28   32   38   35   30   31   45   30   52    35
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

FTE: full time equivalent; GDP: gross domestic product; HCE: healthcare expenditure; ICN: infection control nurse.

P values were calculated by logistic regression using generalised estimating equations, which account for cluster effects by country.

^a^Low/high HCE defined as the share of the GDP ≤ / \> the European mean in 2010 (9%) \[[@r16]\].

^b^Geographical regions according to United Nations grouping \[[@r15]\]; Eastern Europe, Northern Europe, Southern Europe, Western Europe.

^c^Hospital size according to number of acute care beds; ≤ 300 beds, 301 -- 600 beds, \> 600 beds; information available for 294 hospitals.

^d^  ≤ / \>  median defined as FTE ICN (internal staff and external staff) per 1,000 acute care hospital beds ≤ / \> the median of all participating hospitals (3.72 FTE ICN/1,000 beds).

^e^Differences between ≤ 300 beds / 301 -- 600 beds / \> 600 beds p \< 0.05*.*

^f^Differences between low/high HCE p \< 0.05*.*

Feedback on the HCAI situation and hand hygiene compliance
----------------------------------------------------------

In almost all hospitals, healthcare workers (HCW) received feedback on HCAI (n = 106 more than twice a year, n = 61 twice a year, n = 115 once a year, n = 15 less than once a year). Of the 236 hospitals that performed ABHR consumption surveillance, 200 hospitals provided feedback at least once a year (n = 41 more than twice a year, n = 32 twice a year, n = 127 once a year), while in 35 hospitals feedback was given less than once a year and for one hospital information on the frequency of feedback was unavailable. Concerning direct hand hygiene compliance observations, 152 hospitals provided immediate feedback to the observed personnel and 131 hospitals provided a later summary feedback.

As shown in the [Figure](#f1){ref-type="fig"}, IPC committees mainly received data on HCAI (n = 259; 87%) and the proportion of MDRO among HCAIs (n = 245; 83%) but less often on hand hygiene performance indicators. Feedback on MDRO among HCAIs was most often provided in larger hospitals (p = 0.012). IPC committees in hospitals with ICN rates above the European median received significantly more often feedback on hand hygiene compliance data compared to IPC committees in hospitals with ICN rates below the median (p = 0.039). Feedback on hand hygiene performance (ABHR consumption and/or hand hygiene compliance) was significantly more often provided in countries with high HCE (p = 0.042). No feedback was given to IPC committees in 23 (8%) hospitals.

![Feedback of surveillance data to the infection control committees in European acute care hospitals with established healthcare-associated infection surveillance, stratified by healthcare expenditure, infection control nurse rate, United Nation regions and hospital size -- The Prevention of Hospital Infection by Intervention and Training (PROHIBIT) survey, 2011--2012 (n = 297 hospitals)](1700513-f1){#f1}

Discussion
==========

To our knowledge, the data of the PROHIBIT survey offer the first broad analysis of HCAI and MDRO surveillance activities in European acute care hospitals. The findings show that content and methods of surveillance and the role of feedback vary widely across Europe. Hospitals focused more frequently on the surveillance of outcome indicators as BSI and SSI than on PN, CDI or UTI. This may be due to numerous success stories of BSI and SSI preventability, which raised hospitals' awareness towards these two infection types \[[@r17]-[@r19]\].

Fifty-eight per cent of hospitals with SSI surveillance reported to have PDS in place. Such additional surveillance as described by Woelber et al. in 2016, partly prevents under-reporting of SSI in Europe \[[@r20]\]. The finding that HPRO is the most common indicator procedure for SSI surveillance corresponds to the results of ECDC's HAI-Net surveillance of SSI with HPRO being the most frequently reported type of surgery, representing 33% of all operations in 2010--11 \[[@r21]\].

Nevertheless, successful preventability of HCAIs such as PN and UTI has also been described \[[@r22],[@r23]\] and data of the PPS from 2011--12 indicate that respiratory tract infections and UTI are common HCAIs all over Europe. Interestingly, UTI surveillance was significantly more frequently reported in countries with low HCE. Data of the PPS for countries with high HCE however, showed frequencies of UTIs up to 31%, indicating that patients hospitalised in such countries are also at risk for this type of HCAI \[[@r1]\].

Resources are limited; and thus, priorities must be made in HCAI surveillance, even if a broad surveillance strategy including process and outcome indicators is considered helpful to tailor intervention activities for HCAI prevention. Prospective hospital-wide HCAI surveillance is resource-intensive, and in this sense, it was surprising to find that the proportion of hospitals with hospital-wide PN and UTI surveillance was significantly higher in hospitals from countries with low HCE compared to hospitals from countries with high HCE. Generally, hospital-wide surveillance of HCAI is time-consuming and repeated PPSs on HCAI or an automated surveillance linking administrative data and clinical databases including microbiology may be a better approach.

Large healthcare-associated outbreaks of CDI in the first decade of 2000 sparked increased awareness of CDI prevention in Europe, and resulted in European guidelines on CDI prevention in 2008, recommending CDI surveillance \[[@r24]\]. Data of our survey showed that fewer hospitals in countries with low HCE established CDI surveillance, indicating that surveillance activities as a whole may be influenced by financial constraints in Europe. The low level of CDI surveillance activities in these hospitals may be due to absent national CDI surveillance systems, but also to a lack of diagnostic testing and missing awareness as a consequence \[[@r1],[@r25]\]. The high number of hospitals performing CDI surveillance in Northern Europe can be seen as a consequence of public reporting on CDI in the United Kingdom (UK). The new European protocol of CDI surveillance for acute care hospitals, which was developed in 2013, offers a standardised cross-country surveillance, with the option of integrating clinical and molecular data, and can contribute to enhanced monitoring of CDI in all parts of Europe \[[@r26]\].

Although low, still 10% of hospitals in Europe, and nearly 20% of hospitals in Eastern Europe, collect HCAI data by ward personnel only. This method of case finding can be interpreted as a more passive rather than active surveillance, with potential bias of under-reporting. As recommended by the Association for Professionals in Infection Control and Epidemiology (APIC), appropriate education to apply infection surveillance definitions or to perform detailed risk factor collection is indispensable \[[@r27]\].

In addition to the surveillance of outcomes, many hospitals assess data on hand hygiene performance indicators. Monitoring process indicators and assessment of adherence to IPC measures such as hand hygiene observation, enables hospitals to identify gaps and improve adherence to IPC measures more promptly than by focusing on outcome data alone. Interestingly, our study identified a discrepancy between a relatively high number of hospitals monitoring ABHR consumption and a relatively low number of hospitals giving feedback on ABHR consumption data to their IPC committees. This may be due the fact that many hospitals start surveillance activities focusing on outcome indicators and still work on the feedback of these indicators rather on reporting ABHR. In addition, ABHR data are often collected yearly, and thus, may be reported less frequently to IPC committees. On the other hand, process indicators are better candidates to be used for a realistic target-setting both at ward and hospital level. Reference data on these indicators facilitate inter-hospital comparison to support improving their processes \[[@r28]\]. Europe-wide surveys as the ECDC-PPS or PROHIBIT \[[@r1],[@r14]\] already offer reference data on factors such as IPC personnel or isolation capacities and future projects may generate more, possibly stratified reference data for relevant structural and process IPC parameters.

In order to alter their behaviour in HCAI prevention HCWs have to be aware of the problem of HCAI in their setting. Data of our survey indicate that HCWs do receive feedback on HCAI rates in order to raise awareness. However, more research is needed to explore how surveillance data are communicated and perceived, and how this process can be further optimised. Feedback of data may be combined with behaviourally informed approaches such as the setting of long-term goals and encouraging involvement/participation of HCWs for creating local ownership and reflection on achievements and further activities.

Since successful implementation of IPC measures requires the participation of HCWs and other stakeholders, feedback to members of the IPC committee is essential. Especially in smaller hospitals, feedback is not always established yet. In which way the size of a hospital influences feedback of MDRO data to hospitals' stakeholders cannot be fully answered. It can be speculated that larger hospitals see more MDROs, and thus, data are perceived more relevant, particularly because they care more frequently for patients with severe and/or chronic diseases.

In the future, all hospitals' IPC committees should be encouraged to work with MDRO data in order to address supporting organisational factors such as leadership support and communication in MDRO transmission prevention and antibiotic stewardship programmes \[[@r29],[@r30]\].

The current survey gives insight into established surveillance activities of European hospitals. However, there are some limitations:

Participation in the survey was voluntary, and thus, based mainly on hospitals' interest rather than on a randomised sampling process. Therefore, the data may have overestimated surveillance activities in European hospitals. A randomly selected sample would have improved representation of hospitals in Europe. However, the questionnaire could not have been imposed on hospitals, and thus, data quality and the number of participating hospitals might have been lower.

The UN geographical regions are not homogeneous in terms of GDP, healthcare organisation and culture. However, by also reporting data in reference to countries' HCE, we tried to take into account such heterogeneity.

Our findings show that objectives and methods of surveillance vary across Europe. Some outcome indicators, such as BSI, SSI and MRSA, seem to receive considerably more attention than others that are equally important, such as PN, UTI or CDI.

Hospitals' IPC committees mainly receive data on outcome indicators as HCAI and MDRO, but less often on process indicators as hand hygiene performance indicators.

In order to better address prevention of HCAI and antimicrobial resistance in Europe surveillance should be further improved by targeting all relevant HCAI and MDRO and providing active surveillance by trained personnel. To what extent surveillance of process indicators prevent HCAI must be further analysed. In addition, the role of feedback and behaviourally informed approaches should be explored in more detail.
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